Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

The two drugs are metformin, one of the most widely used diabetes medications, and the GLP-1 class of medications that ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

华东医药另一个获批临床试验的产品DR10624注射液为道尔生物自主研发的一款长效三靶点激动剂，适应症为代谢相关脂肪性肝病/代谢相关脂肪性肝炎。截至目前全球尚无同时靶向FGF21R、GLP-1R和GCGR的长效三靶点激动剂药物上市，DR10624注射液具有“first-in-class”潜力。

作者：周绘出品：洞察IPO上交所ShangHai&深交所ShenZhen 新 股 上 ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

本报讯 （记者桂小笋）11月18日，华东医药发布两则创新药研发进展公告。由全资子公司中美华东申报的HDM1005注射液（靶向GLP-1/GIP长效激动剂）临床试验申请已获得FDA批准，可在美国开展Ⅰ期临床试验，适应症为代谢相关脂肪性肝炎（MASH）。

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...